ReNeuron Outlines First-To-Market Plans For Stroke Disability Cell Therapy

 
• By Lucie Ellis-Taitt

ReNeuron has high hopes of being the first to reach the US market with a novel stem cell therapy for use in patients with disabilities caused by stroke – CEO Olav Hellebø outlines the company's plans for Phase III and eventual commercialization.

Brain concept
• Source: Shutterstock

More from Clinical Trials

More from R&D